Health-related quality of life after stereotactic radiosurgery in patients with brain metastases.
Brain metastases
Gamma Knife radiosurgery
Health-related quality of life
LINAC radiosurgery
Stereotactic radiosurgery
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
27 Nov 2023
27 Nov 2023
Historique:
received:
14
06
2023
accepted:
21
11
2023
medline:
28
11
2023
pubmed:
27
11
2023
entrez:
26
11
2023
Statut:
epublish
Résumé
This study aimed to assess health-related quality of life (HRQoL) in patients with brain metastases treated with stereotactic radiosurgery (SRS) and to identify factors associated with this. HRQoL was measured pre-SRS, at 3- and 6-month follow-up. Physical functioning, cognitive functioning, role functioning, and fatigue were analyzed with the EORTC QLQ-C30 questionnaire. Motor dysfunction, future uncertainty, visual disorder, communication deficit, and headaches were analyzed with the EORTC QLQ-BN20. Clinically important symptom or functional impairment was assessed following set thresholds. Factors associated with impairment were identified through multivariable logistic regression analyses. At baseline, 178 patients were included; 54% (n=96) completed questionnaires at 3 months and 39% (n=70) at 6 months. Before SRS, 29% of linear accelerator (LINAC) patients reported physical and cognitive impairment, while 25% reported impairment for fatigue. At 6 months, 39%, 43%, and 57% of LINAC patients reported impairment respectively. Forty-five percent of Gamma Knife (GK) patients reported impairment pre-SRS for physical, cognitive functioning, and fatigue. At 6 months, 48%, 43%, and 33% of GK patients reported impairment respectively. Except for role functioning, pre-SRS symptom and functioning scores were associated with impairment at 3 months, whereas scores at 3 months were associated with impairment at 6 months. Age, gender, systemic therapy, and intracranial progression were not associated with clinically important impairment. As 33-57% of patients with brain metastases reported symptom burden and functional impairments that were of clinical importance, it is recommended to pay attention to the HRQoL outcomes of these patients during clinical encounters.
Identifiants
pubmed: 38008876
doi: 10.1007/s00520-023-08203-6
pii: 10.1007/s00520-023-08203-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
720Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Achrol AS, Rennert RC, Anders C, Soffietti R, Ahluwalia MS, Nayak L et al (2019) Brain metastases. Nat Rev Dis Primers 5(1):1–26
doi: 10.1038/s41572-018-0055-y
Hatiboglu MA, Akdur K, Sawaya R (2020) Neurosurgical management of patients with brain metastasis. Neurosurg Rev 43(2):483–495
doi: 10.1007/s10143-018-1013-6
pubmed: 30058049
Fox BD, Cheung VJ, Patel AJ, Suki D, Rao G (2011) Epidemiology of metastatic brain tumors. Neurosurg Clin N Am 22(1):1–6
doi: 10.1016/j.nec.2010.08.007
pubmed: 21109143
Dhakal S, Peterson CR 3rd, Milano MT (2014) Radiation therapy in the management of patients with limited brain metastases. Am J Clin Oncol 37(2):208–214
doi: 10.1097/COC.0b013e3182546807
pubmed: 22706172
Rastogi K, Bhaskar S, Gupta S, Jain S, Singh D, Kumar P (2018) Palliation of brain metastases: analysis of prognostic factors affecting overall survival. Indian J Palliat Care 24(3):308–312
pubmed: 30111944
pmcid: 6069611
Soffietti R, Kocher M, Abacioglu UM, Villa S, Fauchon F, Baumert BG et al (2013) A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol 31(1):65–72
doi: 10.1200/JCO.2011.41.0639
pubmed: 23213105
Miller JA, Kotecha R, Barnett GH, Suh JH, Angelov L, Murphy ES et al (2017) Quality of life following stereotactic radiosurgery for single and multiple brain metastases. Neurosurgery 81(1):147–155
doi: 10.1093/neuros/nyw166
pubmed: 28327994
Wong E, Zhang L, Rowbottom L, Chiu N, Chiu L, McDonald R et al (2016) Symptoms and quality of life in patients with brain metastases receiving whole-brain radiation therapy. Support Care Cancer 24(11):4747–4759
doi: 10.1007/s00520-016-3326-8
pubmed: 27358169
Verhaak E, Gehring K, Hanssens PEJ, Aaronson NK, Sitskoorn MM (2020) Health-related quality of life in adult patients with brain metastases after stereotactic radiosurgery: a systematic, narrative review. Support Care Cancer 28(2):473–484
doi: 10.1007/s00520-019-05136-x
pubmed: 31792879
Bezjak A, Adam J, Barton R, Panzarella T, Laperriere N, Wong CS et al (2002) Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 38(4):487–496
doi: 10.1016/S0959-8049(01)00150-2
pubmed: 11872340
Reddy NK, Brown FC, Fogarasi MC, Yu JB, Hess J, Chiang VS (2018) Long-term quality of life in survivors of brain metastases: a roller coaster of perspective. Cureus 10(3):e2358
pubmed: 29805927
pmcid: 5963947
Kepka L, Tyc-Szczepaniak D, Osowiecka K, Sprawka A, Trąbska-Kluch B, Czeremszynska B (2018) Quality of life after whole brain radiotherapy compared with radiosurgery of the tumor bed: results from a randomized trial. Clin Transl Oncol 20(2):150–159
doi: 10.1007/s12094-017-1703-5
pubmed: 28616720
Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K et al (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. Jama 295(21):2483–2491
doi: 10.1001/jama.295.21.2483
pubmed: 16757720
Ferini G, Viola A, Valenti V, Tripoli A, Molino L, Marchese VA et al (2022) Whole Brain Irradiation or Stereotactic RadioSurgery for five or more brain metastases (WHOBI-STER): a prospective comparative study of neurocognitive outcomes, level of autonomy in daily activities and quality of life. Clin Transl Radiat Oncol 32:52–58
pubmed: 34926839
Verhaak E, Gehring K, Hanssens PEJ, Sitskoorn MM (2019) Health-related quality of life of patients with brain metastases selected for stereotactic radiosurgery. J Neurooncol 143(3):537–546
doi: 10.1007/s11060-019-03186-z
pubmed: 31073966
pmcid: 6591192
Habets EJ, Dirven L, Wiggenraad RG, Verbeek-de Kanter A, Nijeholt GJ LÀ, Zwinkels H et al (2016) Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study. Neuro Oncol 18(3):435–444
doi: 10.1093/neuonc/nov186
pubmed: 26385615
Harikar MM, Venkataram T, Palmisciano P, Scalia G, Baldoncini M, Cardali SM et al (2023) Comparison of staged stereotactic radiosurgery and fractionated stereotactic radiotherapy in patients with brain metastases > 2 cm without prior whole brain radiotherapy: a systematic review and meta-analysis. World Neurosurg 178:213–32.e6
doi: 10.1016/j.wneu.2023.07.143
pubmed: 37543203
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376
doi: 10.1093/jnci/85.5.365
pubmed: 8433390
Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu MA, Yung WK et al (1996) The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 5(1):139–150
doi: 10.1007/BF00435979
pubmed: 8901377
Rahimy E, Dudley SA, von Eyben R, Pollom EL, Seiger K, Modlin L et al (2021) Phase I/II dose-escalation trial of 3-fraction stereotactic radiosurgery for resection cavities from large brain metastases: health-related quality of life outcomes. Am J Clin Oncol 44(11):588–595
doi: 10.1097/COC.0000000000000868
pubmed: 34670228
Sebastian NT, Glenn C, Hughes R, Raval R, Chu J, DiCostanzo D et al (2020) Linear accelerator-based radiosurgery is associated with lower incidence of radionecrosis compared with gamma knife for treatment of multiple brain metastases. Radiother Oncol 147:136–143
doi: 10.1016/j.radonc.2020.03.024
pubmed: 32294607
Tuleasca C, Negretti L, Faouzi M, Magaddino V, Gevaert T, von Elm E et al (2018) Radiosurgery in the management of brain metastasis: a retrospective single-center study comparing Gamma Knife and LINAC treatment. J Neurosurg 128(2):352–361
doi: 10.3171/2016.10.JNS161480
pubmed: 28338441
Giesinger JM, Loth FLC, Aaronson NK, Arraras JI, Caocci G, Efficace F et al (2020) Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J Clin Epidemiol 118:1–8
doi: 10.1016/j.jclinepi.2019.10.003
pubmed: 31639445
Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S (1998) Using reference data on quality of life--the importance of adjusting for age and gender, exemplified by the EORTC QLQ-C30 (+3). Eur J Cancer 34(9):1381–1389
doi: 10.1016/S0959-8049(98)00136-1
pubmed: 9849421
Nolte S, Liegl G, Petersen MA, Aaronson NK, Costantini A, Fayers PM et al (2019) General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States. Eur J Cancer 107:153–163
doi: 10.1016/j.ejca.2018.11.024
pubmed: 30576971
Salans M, Yip A, Burkeen J, Liu KX, Lee E, Pan-Weisz T et al (2021) Prospective longitudinal assessment of health-related quality of life in patients with brain metastases undergoing radiation therapy. Am J Clin Oncol 44(10):536–543
doi: 10.1097/COC.0000000000000848
pubmed: 34392256
pmcid: 8458239
van der Meer PB, Habets EJJ, Wiggenraad RG, Verbeek-de Kanter A, Nijeholt GJ LÀ, Zwinkels H et al (2018) Individual changes in neurocognitive functioning and health-related quality of life in patients with brain oligometastases treated with stereotactic radiotherapy. J Neurooncol 139(2):359–368
doi: 10.1007/s11060-018-2868-7
pubmed: 29663172
pmcid: 6096889
Qiu X, Zhang N, Pan SJ, Zhao P, Wu BW (2020) Sense of coherence and health-related quality of life in patients with brain metastases. Front Psychol 11:1516
doi: 10.3389/fpsyg.2020.01516
pubmed: 32714254
pmcid: 7343871
Sprangers MA (1996) Response-shift bias: a challenge to the assessment of patients’ quality of life in cancer clinical trials. Cancer Treat Rev 22(Suppl A):55–62
doi: 10.1016/S0305-7372(96)90064-X
pubmed: 8625350
Lin NU, Wefel JS, Lee EQ, Schiff D, van den Bent MJ, Soffietti R et al (2013) Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol 14(10):e407–e416
doi: 10.1016/S1470-2045(13)70308-5
pubmed: 23993385
Skeie BS, Eide GE, Flatebø M, Heggdal JI, Larsen E, Bragstad S et al (2017) Quality of life is maintained using Gamma Knife radiosurgery: a prospective study of a brain metastases patient cohort. J Neurosurg 126(3):708–725
doi: 10.3171/2015.10.JNS15801
pubmed: 27058206
Caissie A, Nguyen J, Chen E, Zhang L, Sahgal A, Clemons M et al (2012) Quality of life in patients with brain metastases using the EORTC QLQ-BN20+2 and QLQ-C15-PAL. Int J Radiat Oncol Biol Phys 83(4):1238–1245
doi: 10.1016/j.ijrobp.2011.09.025
pubmed: 22172909
Snyder C, Brundage M, Rivera YM, Wu AW. A PRO-cision medicine methods toolkit to address the challenges of personalizing cancer care using patient-reported outcomes: introduction to the supplement. Med Care. 2019;57 Suppl 5 Suppl 1(Suppl 5 1):S1-s7.